Fosun Pharma subsidiary gains FDA approval for clinical trial

Shanghai Fosun Pharmaceutical (HKEX: 2196) announced that its subsidiary, MicroH Therapeutics, LLC, has secured approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials for its innovative live biotherapeutic product, LBP-ShC4. The drug is intended for the treatment of androgenetic alopecia (AGA). According to the announcement, as of April 2025, the Group had invested approximately RMB 17 million in the research and development of LBP-ShC4. The company emphasized that the drug's launch remains subject to successful clinical studies and regulatory review, cautioning investors about inherent risks in drug development, including potential safety or efficacy issues that may lead to trial termination. Fosun Pharma will proceed with Phase I clinical trials when conditions are met.